Start Date
August 31, 2008
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2009
efalizumab
1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
Collaborators (1)
Genentech, Inc.
INDUSTRY
Northwestern University
OTHER